M. Sanmamed

Oncology · 2017–2020

A researcher in the Science corpus: 5 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Sanmamed trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. W. Zou
  2. Lieping Chen
  3. S. Rosenberg
  4. Antoni Ribas
  5. C. Robert

Papers from M. Sanmamed's perspective

Ordered by how strongly the researchers M. Sanmamed trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
  2. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (Journal of Experimental Medicine)
  3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  5. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (Science)
  6. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells (Proceedings of the National Academy of Sciences of the United States of America)
  7. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
  8. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)
  9. Signatures of mutational processes in human cancer (Nature)
  10. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. (New England Journal of Medicine)

Their papers